The first main fundraiser of the new Rotary year!
Sporting Dinner 2017 - King's School Marquee
What? - Gloucester Severn Rotary's Sporting Dinner
When? - 6 July 2017
Where? - King's School Marquee
Speakers? - Denis Taylor, Wayne Barnes, MC - Jill Douglas
Cost? - £110 per double
Please support this event as our incoming President has nominated the major beneficiary of this event to be a "Vacuum Assisted Biopsy Machine'
This state-of-the-art piece of equipment will enable the Breast Cancer team to identify this cancer at the earliest opportunity and so allow them to respond rapidly with treatment, whilst also preventing patients with benign tumours from undergoing unnecessary open surgery. Breast cancer is the most commonly diagnosed cancer in women in the UK, with 1 in 8 women (and occasionally men) developing breast cancer. In Gloucestershire some 600 new cases are diagnosed every year, a number which is increasing year on year.
Please support this event and help us to help others with this machine available to Gloucestershire.
More details about this equipment from Richard Smith (head of Fundraising at Cheltenham and Gloucester Hospital Charitiy:
'Vacuum-assisted core biopsy is an alternative to surgical excision biopsy; a safe and minimally invasive procedure in which a sample of breast tissue is removed for examination. Through a small incision in the skin, a special biopsy needle is inserted into the breast and, using a vacuum-powered instrument, several tissue samples are taken. The vacuum draws tissue into the centre of the needle and a rotating cutting device takes the samples. The samples are retrieved from the centre of the biopsy needle following the procedure and sent to a laboratory to be examined by a pathologist (a specialist doctor trained in diagnosing biopsies).
In order to equip our Breast Cancer team with vacuum assisted biopsy equipment, we need to raise £15,000 and will be grateful for any support given to help make this possible. With your support, local patients will benefit from a new technique which identifies cancer at the earliest opportunity allowing our team to respond rapidly with treatment, and which will prevent patients from undergoing unnecessary open surgery.'